Point72 Asset Management
AKCA

Point72 Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Point72 Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-551,300
Closed -$19.3M – 1320
2018
Q3 		$19.3M Buy
+551,300
New +$16.7M 0.08% 306

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management's AKCA Position: Q3 2020 in Review

Point72 Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 257,645 shares — an estimated $3.53M sold.

Point72 Asset Management first reported a position in AKCA in Q4 2019 and held it in 3 quarters. The position peaked at $4.29M in Q4 2019. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

  • Point72 Asset Management reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Point72 Asset Management sold 257,645 Akcea Therapeutics Inc shares in Q3 2020, an estimated $3.53M.
  • Point72 Asset Management first reported a position in Akcea Therapeutics Inc in Q4 2019 and held it in 3 quarters.
  • Point72 Asset Management's Akcea Therapeutics Inc position peaked at $4.29M in Q4 2019.
  • 98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on Point72 Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.